Hilal Bal

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Reactive Oxygen Species

Positive Breast Cancer

Estrogen Receptor

Top Venues

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)